vision loss with tirzepatide Weight-Loss Drug Linked to Lower Risk of Eye Disease in Patients Diabetes | Newsroom vision changes with tirzepatide Medications
Description
Semaglutide is approved as Ozempic (diabetes, December 2017), Wegovy (obesity, June 2021), and, in oral form, the Ozempic pill (diabetes, 2026, which reformulated and renamed Rybelsus) and the Wegovy pill (weight, December 2025)
Hartman ML, et al
There is no MHRA-authorised tirzepatide powder product for patient use in the UK
How New Therapies Like Ozempic, Jardiance, and Mounjaro Shape Cardiovascular Risk The growing body of evidence highlights how specific branded therapies are shaping cardiovascular outcomes in diabetes: Ozempic (semaglutide): Beyond lowering HbA1c, it reduces major adverse cardiovascular events, supports weight loss, and improves lipid profiles
The procedure can reduce the appearance of deep lines, wrinkles and jowls, rejuvenating the face by improving facial contour
Many patients experience mild nausea or fatigue as their body adjusts to the medication
